Paper29237828
Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM and 5 others. J Virol, 2018. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates. Papers, record 29237828. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29237828
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Neutralizing | Major topic |
| Genes, env | Major topic |
| HIV Antibodies | Major topic |
| HIV-1 | Major topic |
| env Gene Products, Human Immunodeficiency Virus | Major topic |
| Amino Acid Sequence | |
| Drug Substitution | |
| Epitopes | |
| HEK293 Cells | |
| HIV Envelope Protein gp120 | |
| HIV Envelope Protein gp160 | |
| HIV Envelope Protein gp41 | |
| HIV Infections | |
| Humans | |
| In Vitro Techniques | |
| Mutation | |
| Neutralization Tests | |
| Phenotype | |
| Protein Conformation |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 AI088610 | NIAID NIH HHS | United States | P01AI088610 | PubMed and NIH | NIH RePORTER |
| R01 AI102718 | NIAID NIH HHS | United States | R01AI102718 | PubMed and NIH | NIH RePORTER |
References103
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15795308 | Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. | J Virol | 2005 | https://conductscience.org/library/papers/15795308 | PubMed |
| 2 | 9371651 | Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. | J Virol | 1997 | https://conductscience.org/library/papers/9371651 | PubMed |
| 3 | 23540694 | Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. | Cell | 2013 | https://conductscience.org/library/papers/23540694 | PubMed |
| 4 | 25965315 | A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site. | Mol Immunol | 2015 | https://conductscience.org/library/papers/25965315 | PubMed |
| 5 | 24068931 | A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. | PLoS Pathog | 2013 | https://conductscience.org/library/papers/24068931 | PubMed |
| 6 | 12487827 | Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. | AIDS Res Hum Retroviruses | 2002 | https://conductscience.org/library/papers/12487827 | PubMed |
| 7 | 19965434 | Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. | Science | 2009 | https://conductscience.org/library/papers/19965434 | PubMed |
| 8 | 21270156 | Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. | J Virol | 2011 | https://conductscience.org/library/papers/21270156 | PubMed |
| 9 | 12646921 | Antibody neutralization and escape by HIV-1. | Nature | 2003 | https://conductscience.org/library/papers/12646921 | PubMed |
| 10 | 10623724 | A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. | J Virol | 2000 | https://conductscience.org/library/papers/10623724 | PubMed |
| 11 | 18653472 | Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. | Mol Biol Cell | 2008 | https://conductscience.org/library/papers/18653472 | PubMed |
| 12 | 17121806 | Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. | J Virol | 2007 | https://conductscience.org/library/papers/17121806 | PubMed |
| 13 | 23086475 | Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. | Nat Med | 2012 | https://conductscience.org/library/papers/23086475 | PubMed |
| 14 | 7543586 | Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. | J Virol | 1995 | https://conductscience.org/library/papers/7543586 | PubMed |
| 15 | 20538861 | Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. | J Virol | 2010 | https://conductscience.org/library/papers/20538861 | PubMed |
| 16 | 18057243 | The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. | J Virol | 2008 | https://conductscience.org/library/papers/18057243 | PubMed |
| 17 | 10888615 | V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. | J Virol | 2000 | https://conductscience.org/library/papers/10888615 | PubMed |
| 18 | 7533854 | Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. | J Virol | 1995 | https://conductscience.org/library/papers/7533854 | PubMed |
| 19 | 20616233 | Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. | Science | 2010 | https://conductscience.org/library/papers/20616233 | PubMed |
| 20 | 17721546 | Broad HIV-1 neutralization mediated by CD4-binding site antibodies. | Nat Med | 2007 | https://conductscience.org/library/papers/17721546 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42065725 | HIV-1 and Vaccine: Analysis of gp41 Target Sequences. | Curr Microbiol | 2026 | https://conductscience.org/library/papers/42065725 | PubMed |
| 37854587 | Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1. | Front Immunol | 2023 | https://conductscience.org/library/papers/37854587 | PubMed |
| 37681958 | Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells. | J Virol | 2023 | https://conductscience.org/library/papers/37681958 | PubMed |
| 35372102 | Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/35372102 | PubMed |
| 35228534 | High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers. | NPJ Vaccines | 2022 | https://conductscience.org/library/papers/35228534 | PubMed |
| 31827000 | Impact of Th1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. | J Virol | 2020 | https://conductscience.org/library/papers/31827000 | PubMed |
| 31523362 | Antiretroviral drug-S for a possible HIV elimination. | Int J Physiol Pathophysiol Pharmacol | 2019 | https://conductscience.org/library/papers/31523362 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| ERVK-20 | 100616444 | PubTator's text mining | https://conductscience.org/library/genes/100616444 | NCBI Gene |
| ITIH4 | 3700 | PubTator's text mining | https://conductscience.org/library/genes/3700 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29237828
GET https://conductscience.org/api/papers/v1/29237828/references?page=2